SERum-bank for PANcreatic Cancer
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: Blood sample.
- Who it may be relevant to
- Registry conditions: Adenocarcinoma. Basic parameters: from 18 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- France
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Overview
This study is about pancreatic cancer. If the diagnostic cancer is done at an early stage (\<2cm), the chances of recovery are very good. But the main problem is there is not any detections means for this cancer. Sadly, when there is a cancer diagnostic , it's already too late in the majority of cases, because the cancer is in an advanced case. Today, there is no any effective means of detection... Blood markers can be a simple means of early detection
Detailed description
The purpose of this study is to establish a sero-library in a case-control cohort to assess several potentially useful serum biomarkers, such as adiponectin in the early diagnosis of pancreatic cancer.
Interventions
- Biological Blood sample
Blood sample will be performed
Primary outcome measures
- Serum adiponectin concentration [Time frame: Months : 0]
Secondary outcome measures (5)
- Serum CA19.9 concentration [Time frame: Months : 0, 3, 6, 9, 12]
- Tumor response and progression rates according to RECIST v1.1 [Time frame: Month 12]
- Progression-free survival [Time frame: Months : 24]
- Overall survival [Time frame: Months : 24]
- Serum adiponectin concentration [Time frame: Months : 3, 6, 9, 12]
Eligibility criteria
ADENOCARCINOMA GROUP
Inclusion criteria
- Documented adenocarcinoma (cytology / anatomopathology), all stages, except if the tumor is immediately resectable and does not require preoperative cytological evidence. In this case, the inclusion and the first collection of the sero bank is done preoperatively. The diagnostic confirmation will therefore be made post-operatively at the risk of being excluded in the event of a different diagnosis.
- At the start of treatment (before surgery / 1st course of chemotherapy)
- Age ≥ 18 years
- Patient affiliated or entitled to a social security system
Exclusion criteria
- Patient refusal
- Acute renal failure
- Child-Pugh B or C cirrhosis
- Patient under guardianship or curators
- Other synchronous cancer or history of cancer <5 years
- Language barrier
CONTROL GROUP
Inclusion criteria
- Age ≥ 40 years
- Patient affiliated or entitled to a social security system
- Digestive endoscopy for any reason other than cancer or chronic inflammatory bowel disease
Exclusion criteria
- Patient refusal
- Acute renal failure
- Child-Pugh B or C cirrhosis
- Patient under guardianship or curators
- Other synchronous cancer or history of cancer <5 years
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: No
Study design
- Observational model
- Cohort
Study locations
France · 2 centers
- CHU Saint-Etienne — Saint-Etienne
- Institut Cancérologique Lucien Newirth (ICLN) — Saint-Priest-en-Jarez
Identifiers
NCT: NCT04374175 · 20CH035 · 2020-A00393-36